Abstract
Abstract only
- Title
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer
- Creators
- Thomas J. Herzog - University of CincinnatiSharad A. Ghamande - Augusta UniversityHani Gabra - Imperial College LondonDeborah Kay Armstrong - Sidney Kimmel Comprehensive Cancer CenterKeiichi Fujiwara - Saitama Medical UniversityBradley J. Monk - University of ArizonaSandro Pignata - MITO and Istituto Nazionale Tumori di Napoli, Naples, Italy;Antonio Gonzalez-Martin - MD Anderson Cancer Center MadridJalid Sehouli - Charité - Universitätsmedizin BerlinCharles Schweizer - MorphotekSusan Weil - MorphotekKimberly Hoffman - MorphotekLuigi Grasso - MorphotekRobert L. Coleman - The University of Texas MD Anderson Cancer CenterIgnace Vergote - Universitair Ziekenhuis Leuven
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.TPS5608-TPS5608
- Identifiers
- 991005969011702656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article